Neuphoria Therapeutics (NEUP) Other Operating Expenses (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Other Operating Expenses of $435193.0 for Q1 2026, up 144.56% year-over-year from $177950.5 in Q1 2025, and down 91.91% quarter-over-quarter from $5.4 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Other Operating Expenses (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Other Operating Expenses for 4 consecutive years, with $435193.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses rose 144.56% year-over-year to $435193.0; the TTM figure through Mar 2026 stood at -$1.0 million (down 118.52% YoY), while the FY2025 annual figure was $239686.0, down 89.14% from the prior year.
- Other Operating Expenses slipped to $435193.0 in Q1 2026 per NEUP's latest filing, from $5.4 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $5.4 million in Q4 2025 and bottomed at -$4.4 million in Q3 2025.
- Historically, Other Operating Expenses has averaged $353902.7 across 4 years, with a median of $177726.0 in 2023.
- Annual changes were most pronounced in 2024 — Other Operating Expenses soared 2407.92% — and 2025, when it plunged 251.98%.
- Neuphoria Therapeutics' Other Operating Expenses stood at $177726.0 in 2023, then soared by 353.18% to $805422.0 in 2024, then soared by 567.91% to $5.4 million in 2025, then sank by 91.91% to $435193.0 in 2026.
- Business Quant data shows NEUP's Other Operating Expenses at $435193.0 in Q1 2026, $5.4 million in Q4 2025, and -$4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 435,193.00 |
| Dec 31, 2025 | 5.38 Mn |
| Sep 30, 2025 | -4.37 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | -976,678.00 |
| Dec 31, 2024 | 805,422.00 |
| Sep 30, 2024 | 2.87 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Mar 31, 2024 | -637,467.00 |
| Dec 31, 2023 | 177,726.00 |
| Sep 30, 2023 | -124,558.00 |